Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening
Romina Lomonaco, Eddison Godinez Leiva, Fernando Bril, et al.
Diabetes Care (2020) Vol. 44, Iss. 2, pp. 399-406
Open Access | Times Cited: 246

Showing 1-25 of 246 citing articles:

AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
Mary E. Rinella, Brent A. Neuschwander‐Tetri, Mohammad Shadab Siddiqui, et al.
Hepatology (2023) Vol. 77, Iss. 5, pp. 1797-1835
Open Access | Times Cited: 1100
American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings
Kenneth Cusi, Scott Isaacs, Diana Barb, et al.
Endocrine Practice (2022) Vol. 28, Iss. 5, pp. 528-562
Open Access | Times Cited: 631
A global view of the interplay between non-alcoholic fatty liver disease and diabetes
Norbert Stefan, Kenneth Cusi
The Lancet Diabetes & Endocrinology (2022) Vol. 10, Iss. 4, pp. 284-296
Closed Access | Times Cited: 391
Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease
Fasiha Kanwal, Jay H. Shubrook, Leon A. Adams, et al.
Gastroenterology (2021) Vol. 161, Iss. 5, pp. 1657-1669
Open Access | Times Cited: 366
A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes
Veeral Ajmera, Sandra Cepin, Kaleb Tesfai, et al.
Journal of Hepatology (2022) Vol. 78, Iss. 3, pp. 471-478
Open Access | Times Cited: 165
Impact of non-invasive biomarkers on hepatology practice: Past, present and future
Quentin M. Anstee, Laurent Castéra, Rohit Loomba
Journal of Hepatology (2022) Vol. 76, Iss. 6, pp. 1362-1378
Open Access | Times Cited: 147
4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2023
Nuha A. ElSayed, Grazia Aleppo, Vanita R. Aroda, et al.
Diabetes Care (2022) Vol. 46, Iss. Supplement_1, pp. s49-s67.2
Open Access | Times Cited: 144
GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives
Riccardo Nevola, Raffaella Epifani, Simona Imbriani, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 2, pp. 1703-1703
Open Access | Times Cited: 120
The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD
Chandani Patel Chavez, Kenneth Cusi, Sushma Kadiyala
The Journal of Clinical Endocrinology & Metabolism (2021) Vol. 107, Iss. 1, pp. 29-38
Open Access | Times Cited: 116
Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease
Diana Barb, Enrico Repetto, Michael Edward Stokes, et al.
Obesity (2021) Vol. 29, Iss. 11, pp. 1950-1960
Open Access | Times Cited: 112
Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis
Elina Cho, C. Ang, Jingxuan Quek, et al.
Gut (2023) Vol. 72, Iss. 11, pp. 2138-2148
Closed Access | Times Cited: 111
Potential screening indicators for early diagnosis of NAFLD/MAFLD and liver fibrosis: Triglyceride glucose index–related parameters
Yan Xue, Jiahui Xu, Man Li, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 99
Fibrosis Progression Rate in Biopsy-Proven Nonalcoholic Fatty Liver Disease Among People With Diabetes Versus People Without Diabetes: A Multicenter Study
Daniel Q. Huang, Laura Wilson, Cynthia Behling, et al.
Gastroenterology (2023) Vol. 165, Iss. 2, pp. 463-472.e5
Open Access | Times Cited: 83
Prevalence of Liver Steatosis and Fibrosis in the General Population and Various High-Risk Populations: A Nationwide Study With 5.7 Million Adults in China
Sailimai Man, Yuhan Deng, Yuan Ma, et al.
Gastroenterology (2023) Vol. 165, Iss. 4, pp. 1025-1040
Open Access | Times Cited: 76
High Prevalence of NASH and Advanced Fibrosis in Type 2 Diabetes: A Prospective Study of 330 Outpatients Undergoing Liver Biopsies for Elevated ALT, Using a Low Threshold
Laurent Castéra, Cédric Laouénan, Anaı̈s Vallet-Pichard, et al.
Diabetes Care (2023) Vol. 46, Iss. 7, pp. 1354-1362
Open Access | Times Cited: 71
4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2024
Nuha A. ElSayed, Grazia Aleppo, Raveendhara R. Bannuru, et al.
Diabetes Care (2023) Vol. 47, Iss. Supplement_1, pp. S52-S76
Open Access | Times Cited: 70
Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis
Daniel Q. Huang, Nabil Noureddin, Veeral Ajmera, et al.
˜The œLancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 9, pp. 829-836
Open Access | Times Cited: 67
The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients With Type 2 Diabetes
Zobair M. Younossi, Pegah Golabi, Jillian Kallman Price, et al.
Clinical Gastroenterology and Hepatology (2024) Vol. 22, Iss. 10, pp. 1999-2010.e8
Closed Access | Times Cited: 55
Role of Insulin Resistance in the Development of Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: From Bench to Patient Care
Juan Patricio Nogueira, Kenneth Cusi
Diabetes Spectrum (2024) Vol. 37, Iss. 1, pp. 20-28
Open Access | Times Cited: 41
Selective Agonists of Thyroid Hormone Receptor Beta for the Treatment of NASH
Kenneth Cusi
New England Journal of Medicine (2024) Vol. 390, Iss. 6, pp. 559-561
Closed Access | Times Cited: 28
Pharmacological Approaches to Nonalcoholic Fatty Liver Disease: Current and Future Therapies
Idoia Genua, Kenneth Cusi
Diabetes Spectrum (2024) Vol. 37, Iss. 1, pp. 48-58
Open Access | Times Cited: 28
Systemic immune-inflammatory biomarkers (SII, NLR, PLR and LMR) linked to non-alcoholic fatty liver disease risk
Ke Liu, Shiyun Tang, Chenhao Liu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 27
Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD
Diana Barb, Srilaxmi Kalavalapalli, Eddison Godinez Leiva, et al.
Journal of Hepatology (2025)
Open Access | Times Cited: 4
Metabolic Dysfunction–Associated Steatotic Liver Disease
Sajjadh M. J. Ali, Michelle Lai
Annals of Internal Medicine (2025)
Closed Access | Times Cited: 1
Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease
Jennifer R. Kramer, Yamini Natarajan, Jianliang Dai, et al.
Hepatology (2021) Vol. 75, Iss. 6, pp. 1420-1428
Open Access | Times Cited: 85
Page 1 - Next Page

Scroll to top